49,854 Shares in OrthoPediatrics Corp. $KIDS Bought by Grandeur Peak Global Advisors LLC

Grandeur Peak Global Advisors LLC purchased a new position in shares of OrthoPediatrics Corp. (NASDAQ:KIDS) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 49,854 shares of the company’s stock, valued at approximately $954,000.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of OrthoPediatrics by 6.9% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,995 shares of the company’s stock worth $246,000 after buying an additional 645 shares in the last quarter. Russell Investments Group Ltd. raised its holdings in OrthoPediatrics by 433.1% in the third quarter. Russell Investments Group Ltd. now owns 1,402 shares of the company’s stock valued at $26,000 after acquiring an additional 1,139 shares in the last quarter. BNP Paribas Financial Markets lifted its stake in OrthoPediatrics by 60.2% in the third quarter. BNP Paribas Financial Markets now owns 3,288 shares of the company’s stock worth $61,000 after acquiring an additional 1,235 shares during the last quarter. Legal & General Group Plc purchased a new stake in shares of OrthoPediatrics in the 2nd quarter valued at approximately $34,000. Finally, Northwestern Mutual Wealth Management Co. increased its position in shares of OrthoPediatrics by 5,226.5% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 2,610 shares of the company’s stock valued at $46,000 after purchasing an additional 2,561 shares during the last quarter. Hedge funds and other institutional investors own 69.05% of the company’s stock.

OrthoPediatrics Trading Down 3.0%

Shares of OrthoPediatrics stock opened at $23.32 on Friday. The company has a current ratio of 4.78, a quick ratio of 2.17 and a debt-to-equity ratio of 0.28. The company has a fifty day simple moving average of $21.32 and a 200-day simple moving average of $18.62. The stock has a market cap of $608.89 million, a price-to-earnings ratio of -13.88 and a beta of 0.98. OrthoPediatrics Corp. has a 12-month low of $14.42 and a 12-month high of $26.74.

OrthoPediatrics (NASDAQ:KIDS) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.04. OrthoPediatrics had a negative net margin of 15.72% and a negative return on equity of 8.10%. The firm had revenue of $70.51 million for the quarter, compared to analyst estimates of $68.21 million. On average, equities analysts forecast that OrthoPediatrics Corp. will post -1.14 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director David R. Pelizzon sold 18,000 shares of the company’s stock in a transaction dated Wednesday, August 26th. The stock was sold at an average price of $24.28, for a total value of $437,040.00. Following the completion of the sale, the director directly owned 6,863,464 shares of the company’s stock, valued at $166,644,905.92. This represents a 0.26% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Jennifer N. Pritzker sold 18,000 shares of the company’s stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $24.28, for a total value of $437,040.00. Following the completion of the sale, the insider directly owned 6,863,464 shares of the company’s stock, valued at approximately $166,644,905.92. This trade represents a 0.26% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 114,900 shares of company stock valued at $2,829,906. 32.50% of the stock is currently owned by insiders.

OrthoPediatrics News Summary

Here are the key news stories impacting OrthoPediatrics this week:

• Positive Sentiment: OrthoPediatrics completed the full U.S. commercial launch of its 3P™ Pediatric Plating Platform® Hip System after more than 350 successful implantations during its limited release. The system expands the company’s pediatric trauma and deformity portfolio and could create a long-term revenue and market-share opportunity, though management did not provide specific financial guidance. 3P Pediatric Plating Platform Hip System launch
• Positive Sentiment: Analyst sentiment remains favorable. Piper Sandler raised its target to $25, Needham lifted its target to $35, and BTIG increased its target to $29, while maintaining positive ratings. MarketBeat data shows a “Moderate Buy” consensus with an average target of $26.44.
• Positive Sentiment: Recent quarterly results exceeded expectations: OrthoPediatrics reported a loss of $0.26 per share versus the estimated loss of $0.30, while revenue of $70.51 million surpassed the $68.21 million consensus estimate. BlackRock and other institutional investors also recently initiated or expanded positions.
• Neutral Sentiment: Reported short interest was listed at zero shares, but an invalid change figure makes the data unreliable and limits its usefulness for assessing short-selling pressure.
• Negative Sentiment: Director David R. Pelizzon and major shareholders associated with Squadron Capital and Jennifer N. Pritzker sold a combined 38,300 shares for approximately $943,302 across August 24–26, at prices ranging from $24.28 to $25.75. The sales reduced their position by roughly 0.56%, leaving ownership of about 6.86 million shares. While modest relative to their remaining stake, repeated insider selling may weigh on investor sentiment, particularly with the stock near its 52-week high. SEC insider transaction filing

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on KIDS shares. Piper Sandler reaffirmed an “overweight” rating and set a $25.00 price objective (up from $22.00) on shares of OrthoPediatrics in a research report on Wednesday, August 5th. BTIG Research raised their price target on OrthoPediatrics from $24.00 to $29.00 and gave the company a “buy” rating in a research note on Thursday, August 20th. Weiss Ratings raised OrthoPediatrics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, August 5th. Needham & Company LLC upped their price objective on OrthoPediatrics from $30.00 to $35.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Finally, TD Cowen reiterated a “buy” rating on shares of OrthoPediatrics in a report on Monday, June 15th. Nine equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $26.44.

OrthoPediatrics Profile

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.